搜索历史清除全部记录
- All
- Product Management
- News
- Introduction
- Enterprise outlets
- FAQ
- Enterprise Video
- Enterprise Atlas
About Us
Zhejiang Angel Biopharm Co., Ltd.
Zhejiang Angel Biopharm Co., Ltd. was established in Xianju, Taizhou, Zhejiang. The company is located in the scenic Xianju Yangfu Industrial Zone; it is a joint venture company by publicly listed company Xianju Pharma and a professional team with many years pharmaceutical experience, mainly focuses on the R&D, production and sales of high-end biopharmaceutical products and high-end sterile APIs.
The main members of the company's management team are from pharmaceutical companies, with an average of more than 15 years of experience. Experienced and dynamic management team is the basis for the company's standardized management and long-term development. The company insists on relying on scientific and technological innovation, taking the road of sustainable development, taking non-steroidal high-end sterile APIs and biopharmaceutical products as the company's development direction. By integrating R&D, production, and sales, we aim to build a comprehensive product portfolio. It strives to become a comprehensive high-tech industrial company covering multiple fields such as medicine, beauty, food and cosmetics.
The company's main product is sodium hyaluronate, which is used in food, cosmetics, medical devices and pharmaceutical products. The company is committed to using its own unique technology to produce high quality products, and pay more attention to the production of high-end sterile Sodium hyaluronate. In addition to its own developed products, the company has close cooperation with university, research institutes and CDMO companies. In the future, the company will pay more attention to new synthesis processes, biopharmaceutical products, and sterile APIs.
The company is currently under construction and will have capacity with more than 200 tons per year. At the same time, the company has already started the construction of the enterprise's quality system and registration of products. It is expected to complete the product registration of NMPA, US FDA and EDQM in 2026.
As a new type of biopharmaceutical manufacturing company, we firmly believe that professionalism and hard work can bring greater value. To become an international high-quality pharmaceutical company is our vision, adhering to the open learning, sharing and cooperative working attitude, and strive to become an angel of human healthcare.
Culture
Open
Focus
Innovation
Cooperation
Honor
